Xbira 250MG Tablet (120’s) is a prescription medication that contains Abiraterone Acetate, a potent anti-androgen agent used primarily in the treatment of prostate cancer. Each tablet contains 250 mg of Abiraterone Acetate, which works by inhibiting the production of androgens, hormones that can promote the growth of prostate cancer cells. This medication is typically prescribed for patients with metastatic castration-resistant prostate cancer, particularly those who have not responded to other treatments. Xbira is often used in combination with other therapies, such as prednisone, to enhance its effectiveness. The drug is available in a bottle containing 120 tablets, making it convenient for long-term treatment regimens. As a targeted therapy, Xbira aims to improve survival rates and quality of life for patients battling advanced prostate cancer.

Abura 250MG Tablet (120’s) is a pharmaceutical product containing Abiraterone Acetate, with each tablet delivering a potent dose of 250 mg of the active ingredient. This medication is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), a condition where prostate cancer continues to progress despite hormone therapy aimed at lowering testosterone levels. Abiraterone Acetate works by inhibiting the enzyme CYP17, which is crucial for the production of androgens, including testosterone, in the adrenal glands and prostate tumor tissue. By reducing androgen levels, Abura helps to slow down the growth of prostate cancer cells. The formulation is designed for oral administration, making it convenient for patients. It is essential for individuals to follow their healthcare provider’s instructions regarding the use of this medication to achieve optimal therapeutic outcomes.

Abura 250MG Tablet, containing Abiraterone Acetate at a dosage of 250mg, is a medication primarily used in the treatment of prostate cancer. This drug works by inhibiting the production of androgens, which are male hormones that can promote the growth of prostate cancer cells. Abura is typically prescribed for patients with metastatic castration-resistant prostate cancer, particularly in combination with other therapies. The tablet is designed for oral administration and is often taken once daily, with or without food. Its active ingredient, Abiraterone Acetate, is a selective inhibitor of the enzyme CYP17, which plays a crucial role in androgen biosynthesis. By reducing androgen levels, Abura helps to slow down the progression of cancer, providing patients with a better quality of life and potentially extending survival.